Hengli(®) Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial

Objective: To evaluate the efficacy and safety of Hengli(®) Chinese botulinum toxin type A (BTX-A; 100 U) in Chinese patients with overactive bladder. Methods: This study was a multicenter, randomized, double-blind, placebo-controlled trial in Chinese patients who were inadequately managed with anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Limin, Liu, Qinggang, Cong, Huiling, Xu, Zhihui, Li, Enhui, Weng, Zhiliang, Jiang, Haihong, Liu, Ben, Huang, Xiao, Xia, Shujie, Wen, Wei, Wu, Juan, Shi, Guowei, Wang, Yang, Li, Peijun, Yu, Yang, Fang, Zujun, Zheng, Jie, Tian, Ye, Shang, Donghao, Li, Hanzhong, Huang, Zhongming, Zhou, Liqun, Xiao, Yunxiang, Zhang, Yaoguang, Wang, Jianlong, Zhang, Xiaodong, Zhang, Peng, Wang, Dongwen, Zhang, Xuhui, Xie, Keji, Wang, Bin, Ma, Lulin, Tian, Xiaojun, Chen, Lijun, Dong, Jinkai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894806/
https://www.ncbi.nlm.nih.gov/pubmed/35250586
http://dx.doi.org/10.3389/fphar.2022.840695

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894806/
https://www.ncbi.nlm.nih.gov/pubmed/35250586
http://dx.doi.org/10.3389/fphar.2022.840695

Ejemplares similares